Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03363165 · ClinicalTrials.gov registry record · Phase 2
Hepatocyte Growth Factor to Improve Functioning in PAD
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT03363165 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 39 participants.
The verdict
NCT03363165, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
HI-PAD is a placebo controlled double-blind randomized pilot clinical trial to determine whether VM202 may improve walking ability in people with lower extremity peripheral artery disease (PAD).
Interventions
- OTHER Placebo
- DRUG VM202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2023-09-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03363165
The ClinicalTrials.gov registry entry for NCT03363165 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03363165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03363165 about?
NCT03363165 is a clinical study titled "Hepatocyte Growth Factor to Improve Functioning in PAD". HI-PAD is a placebo controlled double-blind randomized pilot clinical trial to determine whether VM202 may improve walking ability in people with lower extremity peripheral artery disease (PAD).
What is the current status of trial NCT03363165?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2018-01-01. Estimated completion is 2023-09-05.
What interventions are being tested in trial NCT03363165?
The interventions under investigation include: Placebo (OTHER), VM202 (DRUG).
Who is sponsoring clinical trial NCT03363165?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.